Amyloidosis UK

Registered charity 1183624 · accounts filings on the Charity Commission register · also known as UK ATTR AMYLOIDOSIS PATIENTS' ASSOCIATION (UKATPA)

Latest income
£105k
Latest spending
£54k
Registered
2019
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that Amyloidosis UK generated total income of £105,228 and incurred total expenditure of £52,485, resulting in a surplus of £52,742 for the year ending 31/03/2025. The bank balance at year-end was £73,866.46, with no difference from the bank statement. The independent examiner confirmed that no material matters came to their attention that would cause them to believe the accounts were not prepared in accordance with the Charities Act 2011.

What the accounts disclose

Accounts independently examined (not a full audit).

Public fundraising profile: JustGiving — Amyloidosis UK (matched by registered charity number).

Trustees

Trustee list from the Charity Commission register (current, not historical).

Operates in: Ireland · Northern Ireland · Scotland · Throughout England And Wales

Income and spending

Financial year endIncomeSpending
31/03/2025£105k£54k
31/03/2024£2k£18k
31/03/2023£4k£16k
31/03/2022£33k£31k
31/03/2021£31k£10k

Common questions

Is Amyloidosis UK financially healthy?

The accounts state that Amyloidosis UK generated total income of £105,228 and incurred total expenditure of £52,485, resulting in a surplus of £52,742 for the year ending 31/03/2025. The bank balance at year-end was £73,866.46, with no difference from the bank statement. The independent examiner confirmed that no material matters came to their attention that would cause them to believe the accounts were not prepared in accordance with the Charities Act 2011. Its FY2025 accounts were independently examined.

Funders of similar charities

Funders whose accounts show grants to charities similar to this one (and no recorded grant to this charity) — a starting list for fundraisers.

Charities like this

Semantically similar by activities and financial character, from our analysed corpus. Compare with Blood Cancer UK Research.